Tevogen Logo Notified.png
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days
18 oct. 2024 22h46 HE | Tevogen Bio Inc
WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Madrigal logo.jpg
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
18 oct. 2024 08h00 HE | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31,...
Spyglass Pharma Logo - Long.png
SpyGlass Pharma Presents Promising 18-month Data of its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma
17 oct. 2024 14h35 HE | SpyGlass Pharma, Inc.
Mean intraocular pressure (IOP) was reduced by 43.7% from baseline at month 18All patients remained off topical IOP-lowering medications and achieved >20% IOP reductionAll eyes achieved Visual...
NEW Nephros DkBlueRGB.png
Nephros Delivers Critical Disaster Response to Support Hospitals and Care Facilities Impacted by Hurricanes Helene and Milton
17 oct. 2024 09h00 HE | Nephros, Inc.
SOUTH ORANGE, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH) Nephros, Inc., a leader in advanced filtration technology, is proud to announce its rapid response to the recent...
Biognosys_Logo_Color.png
Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress
17 oct. 2024 08h30 HE | Biognosys AG
Biognosys announced its participation in the 23rd Human Proteome Organization (HUPO) World Congress from October 20 to October 24 in Dresden, Germany.
James (Josh) Wilson Faruqi & Faruqi, LLP
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
16 oct. 2024 10h52 HE | Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options If...
James (Josh) Wilson Faruqi & Faruqi, LLP
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus
16 oct. 2024 10h48 HE | Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their Options If you...
blue-mountain-logo-blue 1 1.png
Blue Mountain Announces Launch of Blue Mountain University: A Premier e-Learning Experience for RAM Software Users
16 oct. 2024 09h00 HE | Blue Mountain
Blue Mountain announces the launch of Blue Mountain University, an eLearning platform for RAM software users to enhance skills, efficiency, and compliance.
60483_BioElectronis.jpg
BioElectronics Corporation's Chairman Updates Investors
16 oct. 2024 08h45 HE | BioElectronics Corporation
Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/...
Logo.jpg
Elicio Therapeutics Reports Inducement Grants
16 oct. 2024 08h30 HE | Elicio Therapeutics Inc.
BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...